Bioo Scientific has launched the T3 Conjugation Kit for targeted in vivo delivery of siRNA or any other RNAi agent.
The T3 Conjugation Kit can also be used for targeted in vitro delivery of siRNA in primary cells or cell lines, which have mixed cell populations.
The company said the technology offers its customers the ability to effectively deliver siRNA or miRNA into any targeted cell or tissue type they are studying.
The T3 technology functions by conjugating a T3 carrier to an antibody that is specific to a receptor or other extracellular domain specific to the targeted cell or tissue type.
The T3 carrier-antibody conjugate can then be loaded with an RNAi agent such as siRNA or miRNA.
The RNAi-agent-loaded T3 conjugate may then be administered systemically or locally to an animal (or cultured cells) where it binds to and is internalised by cells recognised by the antibody.
Once inside the cell the RNAi agent is designed for release from T3, allowing silencing of its intended target.
